X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stake Reduced by Sio Capital Management LLC

Sio Capital Management LLC decreased its position in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 47.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,303,508 shares of the company’s stock after selling 1,196,292 shares during the quarter. X4 Pharmaceuticals comprises about 0.3% of Sio Capital Management LLC’s investment portfolio, making the stock its 26th largest holding. Sio Capital Management LLC owned about 0.77% of X4 Pharmaceuticals worth $872,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its stake in shares of X4 Pharmaceuticals by 46.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after purchasing an additional 12,514 shares in the last quarter. SG Americas Securities LLC acquired a new position in X4 Pharmaceuticals during the 3rd quarter valued at about $37,000. XTX Topco Ltd bought a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth about $65,000. Rhumbline Advisers lifted its stake in shares of X4 Pharmaceuticals by 14.6% in the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after acquiring an additional 23,831 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in shares of X4 Pharmaceuticals by 1,080.3% in the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after acquiring an additional 388,115 shares in the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on XFOR. Stifel Nicolaus dropped their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. HC Wainwright cut their target price on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a research note on Thursday, November 14th.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 239,436 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the sale, the chief executive officer now directly owns 1,057,713 shares of the company’s stock, valued at $581,742.15. The trade was a 18.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Mary Dibiase sold 67,695 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.57, for a total transaction of $38,586.15. Following the transaction, the chief operating officer now owns 452,060 shares in the company, valued at approximately $257,674.20. This trade represents a 13.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 580,800 shares of company stock valued at $321,447. Insiders own 1.62% of the company’s stock.

X4 Pharmaceuticals Trading Up 10.5 %

X4 Pharmaceuticals stock opened at $0.39 on Friday. The firm’s 50 day moving average price is $0.52 and its two-hundred day moving average price is $0.70. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals, Inc. has a twelve month low of $0.26 and a twelve month high of $1.60.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.